Neuro Ophthalmology and Oculoplasty

  • Sayena Jabbehdari
  • Karl C. GolnikEmail author


A variety of conditions may present with symptoms and signs that overlap between the subspecialties of oculoplastics and neuro-ophthalmology. Ideally, co-management of these conditions will be possible but in reality, these subspecialties are under-represented around the world and thus, this may not be feasible. This chapter provides an overview of the most common overlapping conditions and attempts to emphasize the most critical clinical and therapeutic considerations.


Oculoplastic Neuro-Ophthalmology Myasthenia gravis Giant cell arteritis Horner syndrome Idiopathic intracranial hypertension Chronic progressive external ophthalmoplegia Carotid cavernous sinus fistula 

Suggested Readings

  1. 1.
    Smith SV, Lee AG. Update on ocular myasthenia gravis. Neurol Clin. 2017;35(1):115–23.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Jabbehdari S, Golnik KCJAoES. Myasthenia gravis. 2018. 2018;3(5).Google Scholar
  3. 3.
    Thanvi BR, Lo TC. Update on myasthenia gravis. Postgrad Med J. 2004;80(950):690–700.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun. 2014;48–49:143–8.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lee JI, Jander S. Myasthenia gravis: recent advances in immunopathology and therapy. Expert Rev Neurother. 2017;17(3):287–99.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Gwathmey KG, Burns TM. Myasthenia Gravis. Semin Neurol. 2015;35(4):327–39.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Golnik KC, Pena R, Lee AG, Eggenberger ER. An ice test for the diagnosis of myasthenia gravis. Ophthalmology. 1999;106(7):1282–6.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Peragallo JH, Bitrian E, Kupersmith MJ, Zimprich F, Whittaker TJ, Lee MS, et al. Relationship between age, gender, and race in patients presenting with myasthenia gravis with only ocular manifestations. J Neuroophthalmol. 2016;36(1):29–32.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Verschuuren JJ, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev. 2013;12(9):918–23.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;2:44.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wolfe GI, Kaminski HJ, Sonnett JR, Aban IB, Kuo HC, Cutter GR. Randomized trial of thymectomy in myasthenia gravis. J Thorac Dis. 2016;8(12):E1782–3.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Uzawa A, Kawaguchi N, Kanai T, Himuro K, Oda F, Yoshida S, et al. Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis. J Neurol. 2015;262(4):1019–23.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Liu Z, Lai Y, Yao S, Feng H, Zou J, Liu W, et al. Clinical outcomes of thymectomy in myasthenia gravis patients with a history of crisis. World J Surg. 2016;40(11):2681–7.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kaufman AJ, Palatt J, Sivak M, Raimondi P, Lee DS, Wolf A, et al. Thymectomy for myasthenia gravis: complete stable remission and associated prognostic factors in over 1000 cases. Semin Thorac Cardiovasc Surg. 2016;28(2):561–8.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Benatar M, McDermott MP, Sanders DB, Wolfe GI, Barohn RJ, Nowak RJ, et al. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve. 2016;53(3):363–9.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 2011;11:97.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010;41(5):593–8.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71(6):394–9.CrossRefGoogle Scholar
  19. 19.
    Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400–6.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82(9):970–7.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev. 2012;12:CD005081.Google Scholar
  22. 22.
    Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol. 2016;263(8):1473–94.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Dhillon S. Eculizumab: a review in generalized myasthenia gravis. Drugs. 2018;78(3):367–76.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bentley CR, Dawson E, Lee JP. Active management in patients with ocular manifestations of myasthenia gravis. Eye (Lond). 2001;15(Pt 1):18–22.CrossRefGoogle Scholar
  25. 25.
    Brogan K, Farrugia ME, Crofts K. Ptosis surgery in patients with myasthenia gravis: a useful adjunct to medical therapy. Semin Ophthalmol. 2018;33(3):429–34.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Azhar SS, Tang RA, Dorotheo EU. Giant cell arteritis: diagnosing and treating inflammatory disease in older adults. Geriatrics. 2005;60(8):26–30.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Rahman W, Rahman FZ. Giant cell (temporal) arteritis: an overview and update. Surv Ophthalmol. 2005;50(5):415–28.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Salvarani C, Pipitone N, Versari A, Hunder GG. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol. 2012;8(9):509–21.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42(2):311–7.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Brass SD, Durand ML, Stone JH, Chen JW, Stone JR. Case records of the Massachusetts general hospital. Case 36-2008. A 59-year-old man with chronic daily headache. N Engl J Med. 2008;359(21):2267–78.Google Scholar
  31. 31.
    Parikh M, Miller NR, Lee AG, Savino PJ, Vacarezza MN, Cornblath W, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006;113(10):1842–5.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kermani TA, Schmidt J, Crowson CS, Ytterberg SR, Hunder GG, Matteson EL, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012;41(6):866–71.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Costello F, Zimmerman MB, Podhajsky PA, Hayreh SS. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol. 2004;14(3):245–57.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Riordan-Eva P, Landau K, O’Day J. Temporal artery biopsy in the management of giant cell arteritis with neuro-ophthalmic complications. Br J Ophthalmol. 2001;85(10):1248–51.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Nordborg E, Nordborg C. Giant cell arteritis: strategies in diagnosis and treatment. Curr Opin Rheumatol. 2004;16(1):25–30.CrossRefGoogle Scholar
  36. 36.
    McDonnell PJ, Moore GW, Miller NR, Hutchins GM, Green WR. Temporal arteritis. A clinicopathologic study. Ophthalmology. 1986;93(4):518–30.CrossRefGoogle Scholar
  37. 37.
    Sane M, Selvadurai A, Reidy J, Higgs D, Gonzalez-Fernandez F, Lincoff N. Transient visual loss due to reversible ‘pending’ central retinal artery occlusion in occult giant cell arteritis. Eye (Lond). 2014;28(11):1387–90.CrossRefGoogle Scholar
  38. 38.
    Chambers WA, Bernardino VBJJoN-O. Specimen length in temporal artery biopsies. 1988;8(2):121–6.Google Scholar
  39. 39.
    Goodman BW Jr. Temporal arteritis. Am J Med. 1979;67(5):839–52.CrossRefGoogle Scholar
  40. 40.
    Clearkin LG. IV steroids for central retinal artery occlusion in giant-cell arteritis. Ophthalmology. 1992;99(10):1482–4.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Hayreh SS, Biousse V. Treatment of acute visual loss in giant cell arteritis: should we prescribe high-dose intravenous steroids or just oral steroids? J Neuroophthalmol. 2012;32(3):278–87.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Lessell S. Optic neuropathy in giant cell arteritis. J Neuroophthalmol. 2005;25(3):247.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Chan CC, Paine M, O’Day J. Predictors of recurrent ischemic optic neuropathy in giant cell arteritis. J Neuroophthalmol. 2005;25(1):14–7.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–28.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Conway R, O’Neill L, Gallagher P, McCarthy GM, Murphy CC, Veale DJ, et al. Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial. Semin Arthritis Rheum. 2018;48(3):523–8.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Knyazer B, Smolar J, Lazar I, Rosenberg E, Tsumi E, Lifshitz T, et al. Iatrogenic horner syndrome: etiology, diagnosis and outcomes. Isr Med Assoc J. 2017;19(1):34–8.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Jeffery AR, Ellis FJ, Repka MX, Buncic JR. Pediatric Horner syndrome. J AAPOS. 1998;2(3):159–67.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Martin TJ. Horner syndrome: a clinical review. ACS Chem Neurosci. 2018;9(2):177–86.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Bell RL, Atweh N, Ivy ME, Possenti P. Traumatic and iatrogenic Horner syndrome: case reports and review of the literature. J Trauma. 2001;51(2):400–4.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Sadaka A, Schockman SL, Golnik KC. Evaluation of Horner syndrome in the MRI Era. J Neuroophthalmol. 2017;37(3):268–72.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Martin TJ. Horner’s syndrome, Pseudo-Horner’s syndrome, and simple anisocoria. Curr Neurol Neurosci Rep. 2007;7(5):397–406.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Wilhelm H, Ochsner H, Kopycziok E, Trauzettel-Klosinski S, Schiefer U, Zrenner E. Horner’s syndrome: a retrospective analysis of 90 cases and recommendations for clinical handling. Ger J Ophthalmol. 1992;1(2):96–102.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Kanagalingam S, Miller NR. Horner syndrome: clinical perspectives. Eye Brain. 2015;7:35–46.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Czarnecki JS, Pilley SF, Thompson HS. The analysis of anisocoria. The use of photography in the clinical evaluation of unequal pupils. Can J Ophthalmol. 1979;14(4):297–302.Google Scholar
  55. 55.
    Yoo YJ, Yang HK, Hwang JM. Efficacy of digital pupillometry for diagnosis of Horner syndrome. PLoS ONE. 2017;12(6):e0178361.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Al-Moosa A, Eggenberger E. Neuroimaging yield in isolated Horner syndrome. Curr Opin Ophthalmol. 2011;22(6):468–71.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Chen Y, Morgan ML, Barros Palau AE, Yalamanchili S, Lee AG. Evaluation and neuroimaging of the Horner syndrome. Can J Ophthalmol. 2015;50(2):107–11.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Lee JH, Lee HK, Lee DH, Choi CG, Kim SJ, Suh DC. Neuroimaging strategies for three types of Horner syndrome with emphasis on anatomic location. AJR Am J Roentgenol. 2007;188(1):W74–81.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    George A, Haydar AA, Adams WM. Imaging of Horner’s syndrome. Clin Radiol. 2008;63(5):499–505.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Davagnanam I, Fraser CL, Miszkiel K, Daniel CS, Plant GT. Adult Horner’s syndrome: a combined clinical, pharmacological, and imaging algorithm. Eye (Lond). 2013;27(3):291–8.CrossRefGoogle Scholar
  61. 61.
    Beebe JD, Kardon RH, Thurtell MJ. The yield of diagnostic imaging in patients with isolated horner syndrome. Neurol Clin. 2017;35(1):145–51.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Friedman DI. The pseudotumor cerebri syndrome. Neurol Clin. 2014;32(2):363–96.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Wall M, White WN 2nd. Asymmetric papilledema in idiopathic intracranial hypertension: prospective interocular comparison of sensory visual function. Invest Ophthalmol Vis Sci. 1998;39(1):134–42.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Frisen L. Swelling of the optic nerve head: a backstage view of a staging scheme. J Neuroophthalmol. 2017;37(1):3–6.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Kesler A, Goldhammer Y, Hadayer A, Pianka P. The outcome of pseudotumor cerebri induced by tetracycline therapy. Acta Neurol Scand. 2004;110(6):408–11.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Lee AG. Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne. Cutis. 1995;55(3):165–8.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Caruana DM, Wylie G. ‘Washout’ period for oral tetracycline antibiotics prior to systemic isotretinoin. Br J Dermatol. 2016;174(4):929–30.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Fraser JA, Bruce BB, Rucker J, Fraser LA, Atkins EJ, Newman NJ, et al. Risk factors for idiopathic intracranial hypertension in men: a case-control study. J Neurol Sci. 2010;290(1–2):86–9.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Wardly D, Wolford LM, Veerappan V. Idiopathic intracranial hypertension eliminated by counterclockwise maxillomandibular advancement: a case report. Cranio. 2017;35(4):259–67.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Henry M, Driscoll MC, Miller M, Chang T, Minniti CP. Pseudotumor cerebri in children with sickle cell disease: a case series. Pediatrics. 2004;113(3 Pt 1):e265–9.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    van Gelder T, van Gemert HM, Tjiong HL. A patient with megaloblastic anaemia and idiopathic intracranial hypertension. Case history. Clin Neurol Neurosurg. 1991;93(4):321–2.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Tugal O, Jacobson R, Berezin S, Foreman S, Berezin S, Brudnicki A, et al. Recurrent benign intracranial hypertension due to iron deficiency anemia. Case report and review of the literature. Am J Pediatr Hematol Oncol. 1994;16(3):266–70.Google Scholar
  73. 73.
    Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry. 2012;83(5):488–94.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Keltner JL. Optic nerve sheath decompression. How does it work? Has its time come? Arch Ophthalmol. 1988;106(10):1365–9.Google Scholar
  75. 75.
    Spoor TC, Ramocki JM, Madion MP, Wilkinson MJ. Treatment of pseudotumor cerebri by primary and secondary optic nerve sheath decompression. Am J Ophthalmol. 1991;112(2):177–85.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Flynn WJ, Westfall CT, Weisman JS. Transient blindness after optic nerve sheath fenestration. Am J Ophthalmol. 1994;117(5):678–9.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Huang LC, Winter TW, Herro AM, Rosa PR, Schiffman JC, Pasol J, et al. Ventriculoperitoneal shunt as a treatment of visual loss in idiopathic intracranial hypertension. J Neuroophthalmol. 2014;34(3):223–8.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Tarnaris A, Toma AK, Watkins LD, Kitchen ND. Is there a difference in outcomes of patients with idiopathic intracranial hypertension with the choice of cerebrospinal fluid diversion site: a single centre experience. Clin Neurol Neurosurg. 2011;113(6):477–9.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Abubaker K, Ali Z, Raza K, Bolger C, Rawluk D, O’Brien D. Idiopathic intracranial hypertension: lumboperitoneal shunts versus ventriculoperitoneal shunts–case series and literature review. Br J Neurosurg. 2011;25(1):94–9.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Farb RI, Vanek I, Scott JN, Mikulis DJ, Willinsky RA, Tomlinson G, et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology. 2003;60(9):1418–24.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Radvany MG, Solomon D, Nijjar S, Subramanian PS, Miller NR, Rigamonti D, et al. Visual and neurological outcomes following endovascular stenting for pseudotumor cerebri associated with transverse sinus stenosis. J Neuroophthalmol. 2013;33(2):117–22.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Purvin VA, Trobe JD, Kosmorsky G. Neuro-ophthalmic features of cerebral venous obstruction. Arch Neurol. 1995;52(9):880–5.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Bono F, Giliberto C, Mastrandrea C, Cristiano D, Lavano A, Fera F, et al. Transverse sinus stenoses persist after normalization of the CSF pressure in IIH. Neurology. 2005;65(7):1090–3.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Ahmed RM, Wilkinson M, Parker GD, Thurtell MJ, Macdonald J, McCluskey PJ, et al. Transverse sinus stenting for idiopathic intracranial hypertension: a review of 52 patients and of model predictions. AJNR Am J Neuroradiol. 2011;32(8):1408–14.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Ahmed R, Friedman DI, Halmagyi GM. Stenting of the transverse sinuses in idiopathic intracranial hypertension. J Neuroophthalmol. 2011;31(4):374–80.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Shemesh A, Margolin E. Kearns Sayre syndrome. Treasure Island (FL): StatPearls; 2018.Google Scholar
  87. 87.
    McClelland C, Manousakis G, Lee MS. Progressive external ophthalmoplegia. Curr Neurol Neurosci Rep. 2016;16(6):53.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Bucelli RC, Lee MS, McClelland CM. Chronic progressive external ophthalmoplegia in the absence of ptosis. J Neuroophthalmol. 2016;36(3):270–4.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Ahn J, Kim NJ, Choung HK, Hwang SW, Sung M, Lee MJ, et al. Frontalis sling operation using silicone rod for the correction of ptosis in chronic progressive external ophthalmoplegia. Br J Ophthalmol. 2008;92(12):1685–8.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Richardson C, Smith T, Schaefer A, Turnbull D, Griffiths P. Ocular motility findings in chronic progressive external ophthalmoplegia. Eye (Lond). 2005;19(3):258–63.CrossRefGoogle Scholar
  91. 91.
    Mullie MA, Harding AE, Petty RK, Ikeda H, Morgan-Hughes JA, Sanders MD. The retinal manifestations of mitochondrial myopathy. A study of 22 cases. Arch Ophthalmol. 1985;103(12):1825–30.Google Scholar
  92. 92.
    Ota Y, Miyake Y, Awaya S, Kumagai T, Tanaka M, Ozawa T. Early retinal involvement in mitochondrial myopathy with mitochondrial DNA deletion. Retina. 1994;14(3):270–6.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Meire F, De Laey JJ, de Bie S, van Staey M, Matton MT. Dominant optic nerve atrophy with progressive hearing loss and chronic progressive external ophthalmoplegia (CPEO). Ophthalmic Paediatr Genet. 1985;5(1–2):91–7.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Gonzalez-Moron D, Bueri J, Kauffman MA. Progressive external ophthalmoplegia (PEO) due to a mutation in the C10orf2 (PEO1) gene mimicking a myasthenic crisis. BMJ Case Rep. 2013;2013.Google Scholar
  95. 95.
    Behbehani R, Sharfuddin K, Anim JT. Mitochondrial ophthalmoplegia with fatigable weakness and elevated acetylcholine receptor antibody. J Neuroophthalmol. 2007;27(1):41–4.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Miller NR WF, Hoyt WF. Walsh and Hoyt’s clinical neuro-ophthalmology, 6th ed. Philadelphia, PA, London: Lippincott Williams & Wilkins; 2005.Google Scholar
  97. 97.
    Lapid O, Lapid-Gortzak R, Barr J, Rosenberg L. Eyelid crutches for ptosis: a forgotten solution. Plast Reconstr Surg. 2000;106(5):1213–4.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    de Castro FA, Cruz AA, Sobreira CF. Brow motility in mitochondrial myopathy. Ophthalmic Plast Reconstr Surg. 2010;26(6):416–9.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Wallace DK, Sprunger DT, Helveston EM, Ellis FD. Surgical management of strabismus associated with chronic progressive external ophthalmoplegia. Ophthalmology. 1997;104(4):695–700.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Tinley C, Dawson E, Lee J. The management of strabismus in patients with chronic progressive external ophthalmoplegia. Strabismus. 2010;18(2):41–7.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Chaudhry IA, Elkhamry SM, Al-Rashed W, Bosley TM. Carotid cavernous fistula: ophthalmological implications. Middle East Afr J Ophthalmol. 2009;16(2):57–63.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Barrow DL, Spector RH, Braun IF, Landman JA, Tindall SC, Tindall GT. Classification and treatment of spontaneous carotid-cavernous sinus fistulas. J Neurosurg. 1985;62(2):248–56.CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Zhu L, Liu B, Zhong J. Post-traumatic right carotid-cavernous fistula resulting in symptoms in the contralateral eye: a case report and literature review. BMC Ophthalmol. 2018;18(1):183.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Fattahi TT, Brandt MT, Jenkins WS, Steinberg B. Traumatic carotid-cavernous fistula: pathophysiology and treatment. J Craniofac Surg. 2003;14(2):240–6.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Ellis JA, Goldstein H, Connolly ES Jr, Meyers PM. Carotid-cavernous fistulas. Neurosurg Focus. 2012;32(5):E9.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Gupta AK, Purkayastha S, Krishnamoorthy T, Bodhey NK, Kapilamoorthy TR, Kesavadas C, et al. Endovascular treatment of direct carotid cavernous fistulae: a pictorial review. Neuroradiology. 2006;48(11):831–9.CrossRefPubMedPubMedCentralGoogle Scholar
  107. 107.
    Badilla J, Haw C, Rootman J. Superior ophthalmic vein cannulation through a lateral orbitotomy for embolization of a cavernous dural fistula. Arch Ophthalmol. 2007;125(12):1700–2.CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    Goldberg RA, Goldey SH, Duckwiler G, Vinuela F. Management of cavernous sinus-dural fistulas. Indications and techniques for primary embolization via the superior ophthalmic vein. Arch Ophthalmol. 1996;114(6):707–14.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Ophthalmology and Visual SciencesUniversity of Illinois at ChicagoIllinoisUSA
  2. 2.Department of OphthalmologyUniversity of Cincinnati Medical CenterCincinnatiUSA
  3. 3.Cincinnati Eye InstituteCincinnatiUSA

Personalised recommendations